L
Laura A. Johnson
Researcher at University of Pennsylvania
Publications - 49
Citations - 7247
Laura A. Johnson is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Immunotherapy & Antigen. The author has an hindex of 26, co-authored 48 publications receiving 6122 citations. Previous affiliations of Laura A. Johnson include Duke University & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.
Mojgan Ahmadzadeh,Laura A. Johnson,Bianca Heemskerk,John R. Wunderlich,Mark E. Dudley,Donald E. White,Steven A. Rosenberg +6 more
TL;DR: It is suggested that the tumor microenvironment can lead to up-regulation of PD-1 on tumor-reactive T cells and contribute to impaired antitumor immune responses.
Journal ArticleDOI
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
Laura A. Johnson,Richard A. Morgan,Mark E. Dudley,Lydie Cassard,James Chih-Hsin Yang,Michael S. Hughes,Udai S. Kammula,Richard E. Royal,Richard M. Sherry,John R. Wunderlich,Chyi-Chia Richard Lee,Nicholas P. Restifo,Susan L. Schwarz,Alexandria P. Cogdill,Rachel Bishop,Hung Kim,Carmen C. Brewer,Susan F. Rudy,Carter VanWaes,Jeremy L. Davis,Aarti Mathur,Robert T. Ripley,Debbie Ann N. Nathan,Carolyn M. Laurencot,Steven A. Rosenberg +24 more
TL;DR: T cells expressing highly reactive TCRs mediate cancer regression in humans and target rare cognate-antigen-containing cells throughout the body, a finding with important implications for the gene therapy of cancer.
Journal ArticleDOI
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.
Avery D. Posey,Robert D. Schwab,Alina C. Boesteanu,Catharina Steentoft,Ulla Mandel,Boris Engels,Jennifer D. Stone,Thomas Daugbjerg Madsen,Karin Schreiber,Kathleen M. Haines,Alexandria P. Cogdill,Taylor J. Chen,Decheng Song,John Scholler,David M. Kranz,Michael Feldman,Regina M. Young,Brian Keith,Hans Schreiber,Henrik Clausen,Laura A. Johnson,Carl H. June +21 more
TL;DR: This work developed a CAR that recognized cancer-associated Tn glycoform of MUC1, a neoantigen expressed in a variety of cancers and established that abnormal self-antigens can serve as targets for tumor rejection.
Journal ArticleDOI
Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma
Laura A. Johnson,John Scholler,Takayuki Ohkuri,Akemi Kosaka,Prachi R. Patel,Shannon E. McGettigan,Arben Nace,Tzvete Dentchev,Pramod Thekkat,Andreas Loew,Alina C. Boesteanu,Alexandria P. Cogdill,Taylor Chen,Joseph A. Fraietta,Christopher C. Kloss,Avery D. Posey,Boris Engels,Reshma Singh,Tucker Ezell,Neeraja Idamakanti,Melissa Ramones,Na Li,Li Zhou,Gabriela Plesa,John T. Seykora,Hideho Okada,Carl H. June,Jennifer Brogdon,Marcela V. Maus +28 more
TL;DR: A low-affinity single-chain variable fragment was specific for EGFRvIII over wild-type EGFR and CAR T cells transduced with this fragment were able to target antigen-expressing cells in vitro and in vivo in multiple mouse xenograft models of human glioblastoma.
Journal ArticleDOI
Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.
Liang-Chuan S. Wang,Albert C. Lo,John Scholler,Jing Sun,Rajrupa S. Majumdar,Veena Kapoor,Michael Antzis,Cody E. Cotner,Laura A. Johnson,Amy C. Durham,Charalambos C. Solomides,Carl H. June,Ellen Puré,Steven M. Albelda +13 more
TL;DR: It is shown that inhibiting tumor growth by targeting tumor stroma with adoptively transferred CAR T cells directed to FAP can be safe and effective, suggesting that further clinical development of anti-human FAP-CAR is warranted.